Author
Piovella F
Bio: Piovella F is an academic researcher. The author has contributed to research in topics: Dabigatran. The author has an hindex of 1, co-authored 1 publications receiving 378 citations.
Topics: Dabigatran
Papers
More filters
••
TL;DR: In this paper, a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral Dabigatran etexilate (50, 150,mg twice daily, 300,mg once daily, 225, mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) starting 12 h prior to surgery.
390 citations
Cited by
More filters
••
TL;DR: The ASRA consensus statements represent the collective experience of recognized experts in the field of neuraxial anesthesia and anticoagulation and are based on case reports, clinical series, pharmacology, hematology, and risk factors for surgical bleeding.
1,319 citations
••
TL;DR: Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile.
1,103 citations
••
TL;DR: Dabigatran etexilate (220 mg or 150‰mg) was at least as effective as enoxaparin and had a similar safety profile for prevention of VTE after total knee replacement surgery.
991 citations
••
TL;DR: The data suggest that dabigatran etexilate is a promising novel oral DTI with predictable PK and PD characteristics and good tolerability, and further investigation of dabig atran e Texilate for the treatment and prophylaxis of patients with arterial and venous thromboembolic disorders, acute coronary syndromes and other medical conditions is warranted.
Abstract: Aims
The novel direct thrombin inhibitor (DTI), dabigatran etexilate (Boehringer Ingelheim Pharma GmbH & Co. KG), shows potential as an oral antithrombotic agent. Two double-blind, randomized trials were undertaken to investigate the pharmacokinetics (PK), pharmacodynamics (PD) and tolerability of orally administered dabigatran etexilate in healthy male subjects.
855 citations
••
TL;DR: Individual benefit-risk might be improved by tailoring dabigatran dose after considering selected patient characteristics, and the risk of ischemic stroke and bleeding outcomes were correlated with dabig atran plasma concentrations.
760 citations